Friday’s Midday Stock Update: Agios Pharma (AGIO), Sangamo Biosciences (SGMO), Sarepta Therapeutics (SRPT), Glu Mobile (GLUU), Karyopharm Therapeutics (KPTI)

By Carrie Williams

So far Friday, November 8, NASDAQ is up 1.09% and the S&P is up 0.49%. Here are this morning’s most active stocks: Agios Pharma (AGIOResearch Report), Sangamo Biosciences (SGMOResearch Report), Sarepta Therapeutics (SRPTResearch Report), Glu Mobile (GLUUResearch Report) and Karyopharm Therapeutics (KPTIResearch Report).

Agios Pharma is up 8.82% in midday trading to $34.92. Shares opened today at $32.09. The company has a 52-week low of $28.36 and a 52-week high of $71.32. On the Street’s front, the average 12-month analyst price target for the stock is $60.14, marking a 87.41% potential upside from current levels. In a report issued on November 5, Guggenheim analyst Michael Schmidt maintained a Buy rating on AGIO, with a price target of $52.00, which represents a potential upside of 62% from where the stock is currently trading. Separately, on October 21, Goldman Sachs’ Salveen Richter maintained a Hold rating on the stock and has a price target of $40.00.

Sangamo Biosciences is up 6.67% in midday trading to $9.92. Shares opened today at $9.30. The company has a 52-week low of $6.26 and a 52-week high of $13.91. On the Street’s front, the average 12-month analyst price target for the stock is $13.50, marking a 45.16% potential upside from current levels. In a report released yesterday, Cowen analyst Ritu Baral maintained a Buy rating on SGMO. Separately, on August 12, Wedbush’s Liana Moussatos reiterated a Hold rating on the stock and has a price target of $11.00.

Sarepta Therapeutics is up 6.54% in midday trading to $96.96. Shares opened today at $91.00. The company has a 52-week low of $72.05 and a 52-week high of $158.80. On the Street’s front, the average 12-month analyst price target for the stock is $190.94, marking a 109.82% potential upside from current levels. In a report released today, Credit Suisse analyst Martin Auster maintained a Buy rating on SRPT, with a price target of $185.00, which implies an upside of 103% from current levels. Separately, on October 8, Oppenheimer’s Hartaj Singh maintained a Hold rating on the stock . Over the last 3 months, the insider sentiment on Sarepta Therapeutics has been positive based on 33 corporate insider transactions. This sentiment is slightly higher than the average sector sentiment of insiders.

See today’s analyst top recommended stocks >>

Glu Mobile is up 6.48% in midday trading to $5.84. Shares opened today at $5.48. The company has a 52-week low of $4.11 and a 52-week high of $11.75. On the Street’s front, the average 12-month analyst price target for the stock is $7.29, marking a 33.03% potential upside from current levels. In a report released yesterday, Wedbush analyst Michael Pachter reiterated a Buy rating on GLUU, with a price target of $7.50, which represents a potential upside of 37% from where the stock is currently trading. Separately, on August 19, Roth Capital’s Darren Aftahi maintained a Hold rating on the stock and has a price target of $7.00. Over the last 3 months, the insider sentiment on Glu Mobile has been negative based on 41 corporate insider transactions. This sentiment is lower than the average sector sentiment of insiders.

Karyopharm Therapeutics is up 6.4% in midday trading to $15.13. Shares opened today at $14.22. The company has a 52-week low of $3.92 and a 52-week high of $15.22. On the Street’s front, the average 12-month analyst price target for the stock is $23.60, marking a 65.96% potential upside from current levels. In a report issued on November 6, Wedbush analyst David Nierengarten maintained a Buy rating on KPTI, with a price target of $18.00, which represents a potential upside of 27% from where the stock is currently trading.

Trending Stocks Based on Insider Activity >>